B. Lawrence

Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.

L. Frohman, J. Castaigne, S. Teichman, 2006, The Journal of clinical endocrinology and metabolism.

Phase I Study of GRN1005 in Recurrent Malignant Glioma

T. Mikkelsen, P. Wen, S. Rosenfeld, 2013, Clinical Cancer Research.

Dynamic ctDNA mutational complexity in melanoma patients receiving immunotherapy

Euan J. Rodger, C. Print, M. Eccles, 2022, medRxiv.

Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse.

L. Frohman, R. Salvatori, J. Castaigne, 2006, American journal of physiology. Endocrinology and metabolism.

Evaluation of CNS and peripheral antitumor activity of ANG1005 in patients with brain metastases from breast tumors and other advanced solid tumors.

S. Bates, S. Kesari, R. Kurzrock, 2014 .

Abstract B49: GRN1005 phase I studies: Final results.

T. Mikkelsen, P. Wen, S. Rosenfeld, 2011 .

ANG1005: Results of a phase I study in patients with advanced solid tumors and brain metastases.

A. Brenner, R. Kurzrock, S. Moulder, 2010 .

Abstract OT1-06-01: ANG1005 in leptomeningeal disease (ANGLeD) trial: A randomized, open-label, phase 3 study of ANG1005 compared with Physician's Best Choice in HER2-negative breast cancer patients with newly diagnosed leptomeningeal carcinomatosis and previously treated brain metastases

N. Ibrahim, P. Kumthekar, R. Mazanet, 2019, Ongoing Clinical Trials.